云南白药
(000538)
| 流通市值：1024.84亿 | | | 总市值：1033.45亿 |
| 流通股本：17.69亿 | | | 总股本：17.84亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 29,915,155,069.84 | 20,455,286,287.52 | 10,774,290,921.49 | 39,111,292,156 |
| 营业收入 | 29,915,155,069.84 | 20,455,286,287.52 | 10,774,290,921.49 | 39,111,292,156 |
| 二、营业总成本 | 25,480,753,830.78 | 17,225,017,022.4 | 8,984,420,592.95 | 35,082,749,923.97 |
| 营业成本 | 21,418,846,898.48 | 14,462,809,950.85 | 7,544,467,227.29 | 28,744,517,640.29 |
| 税金及附加 | 168,054,488.16 | 119,551,819.49 | 55,093,111.34 | 210,801,478.72 |
| 销售费用 | 3,306,476,038.21 | 2,296,821,490.59 | 1,233,362,282.58 | 4,992,157,591.11 |
| 管理费用 | 499,576,143.13 | 327,410,020.48 | 161,437,289.24 | 1,058,503,523.9 |
| 研发费用 | 216,182,636.47 | 148,043,019.34 | 57,282,132.5 | 336,013,434.83 |
| 财务费用 | -128,382,373.67 | -129,619,278.35 | -67,221,450 | -259,243,744.88 |
| 其中:利息费用 | 43,590,724.86 | 27,648,907.91 | 11,399,686.71 | 49,601,252.93 |
| 其中:利息收入 | 188,534,092.24 | 162,711,635.16 | 82,361,318.19 | 315,758,812.17 |
| 加:公允价值变动收益 | -18,774,131.35 | 4,596,876.81 | -19,523,287.53 | 123,566,330.46 |
| 加:投资收益 | 685,143,202.78 | 477,498,314.49 | 244,226,086.31 | 779,010,728.82 |
| 资产处置收益 | -1,484,474.56 | -1,592,134.63 | -661,899.99 | 10,654,438.38 |
| 资产减值损失(新) | -14,007,824.42 | -3,578,594.53 | 3,997,550 | -58,127,562.23 |
| 信用减值损失(新) | -130,560,162.1 | -82,762,335.12 | -137,303,764.6 | -136,455,204.36 |
| 其他收益 | 56,171,205.6 | 47,920,871.74 | 37,414,865.31 | 83,315,147.32 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 5,010,889,055.01 | 3,672,352,263.88 | 1,918,019,878.04 | 4,830,506,110.42 |
| 加:营业外收入 | 11,699,322.27 | 4,431,701.71 | 2,331,992.88 | 12,234,049.26 |
| 减:营业外支出 | 9,337,106.67 | 4,755,624.76 | 657,580.22 | 24,728,403.02 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 5,013,251,270.61 | 3,672,028,340.83 | 1,919,694,290.7 | 4,818,011,756.66 |
| 减:所得税费用 | 683,550,780.58 | 482,065,489.87 | 220,647,885.7 | 695,450,660.17 |
| 六、净利润 | 4,329,700,490.03 | 3,189,962,850.96 | 1,699,046,405 | 4,122,561,096.49 |
| 持续经营净利润 | 4,329,700,490.03 | 3,189,962,850.96 | 1,699,046,405 | 4,122,561,096.49 |
| 归属于母公司股东的净利润 | 4,326,728,068.05 | 3,188,829,903.1 | 1,701,931,446 | 4,093,782,074.02 |
| 少数股东损益 | 2,972,421.98 | 1,132,947.86 | -2,885,041 | 28,779,022.47 |
| (一)基本每股收益 | 2.42 | 1.79 | 0.95 | 2.29 |
| (二)稀释每股收益 | 2.42 | 1.79 | 0.95 | 2.29 |
| 八、其他综合收益 | -5,079,332.38 | -8,020,440.18 | -962,931.86 | -21,847,821.78 |
| 归属于母公司股东的其他综合收益 | -4,915,956.31 | -8,367,865.6 | -1,009,331.56 | -21,450,521.18 |
| 九、综合收益总额 | 4,324,621,157.65 | 3,181,942,410.78 | 1,698,083,473.14 | 4,100,713,274.71 |
| 归属于母公司股东的综合收益总额 | 4,321,812,111.74 | 3,180,462,037.5 | 1,700,922,114.44 | 4,072,331,552.84 |
| 归属于少数股东的综合收益总额 | 2,809,045.91 | 1,480,373.28 | -2,838,641.3 | 28,381,721.87 |
| 公告日期 | 2024-10-30 | 2024-08-27 | 2024-04-27 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |